Cargando…

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease

ABSTRACT: Excessive intrahepatocellular lipid accumulation or steatosis is caused by abnormal lipid metabolism and a common character of nonalcoholic fatty liver disease (NAFLD), which may progress into cirrhosis and hepatocellular cancer. Andrographolide (Andro) is the primary active ingredient ext...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ran, Li-Sha, Wu, Ya-Zeng, Gan, Yi-Wen, Wang, Hong-Lian, Wu, Li-Juan, Zheng, Chun-Mei, Ming, Yao, Xiong, Ran, Li, Yong-Lin, Lei, Shi-Hang, Wang, Xue, Lao, Xiao-Qing, Zhang, Hong-Min, Wang, Li, Chen, Chen, Zhao, Chang-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810587/ https://www.ncbi.nlm.nih.gov/pubmed/36115008 http://dx.doi.org/10.1007/s11418-022-01647-w

Ejemplares similares

Overexpression of CD36 and Acyl-CoA Synthetases FATP2, FATP4 and ACSL1 Increases Fatty Acid Uptake in Human Hepatoma Cells
por: Krammer, Julia, et al.
Publicado: (2011)

Overexpressed FATP1, ACSVL4/FATP4 and ACSL1 Increase the Cellular Fatty Acid Uptake of 3T3-L1 Adipocytes but Are Localized on Intracellular Membranes
por: Zhan, Tianzuo, et al.
Publicado: (2012)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients
por: Wang, Qingling, et al.
Publicado: (2022)

ApoB siRNA-induced Liver Steatosis is Resistant to Clearance by the Loss of Fatty Acid Transport Protein 5 (Fatp5)
por: Ason, Brandon, et al.
Publicado: (2011)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
por: Ulasoglu, Celal, et al.
Publicado: (2021)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2017)

Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice
por: Rom, Oren, et al.
Publicado: (2019)

Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment
por: Shao, Congxiang, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

Fatty acid transport protein-5 (FATP5) deficiency enhances hepatocellular carcinoma progression and metastasis by reprogramming cellular energy metabolism and regulating the AMPK-mTOR signaling pathway
por: Wang, Ming-Da, et al.
Publicado: (2021)

Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2020)

Novel role of FATP1 in mitochondrial fatty acid oxidation in skeletal muscle cells
por: Sebastián, David, et al.
Publicado: (2009)

Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
por: Mukai, Takako, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease: Noninvasive Methods of Diagnosing Hepatic Steatosis
por: AlShaalan, Rasha, et al.
Publicado: (2015)

Herbicide Widespread: The Effects of Pethoxamid on Nonalcoholic Fatty Liver Steatosis In Vitro
por: Pirozzi, Anna Virginia Adriana, et al.
Publicado: (2020)

Hepatic Steatosis in Infancy: The Beginning of Pediatric Nonalcoholic Fatty Liver Disease?
por: McNelis, Kera, et al.
Publicado: (2021)

Enterotoxigenic Escherichia coli Interferes FATP4-Dependent Long-Chain Fatty Acid Uptake of Intestinal Epithelial Enterocytes via Phosphorylation of ERK1/2-PPARγ Pathway
por: Li, Zhi, et al.
Publicado: (2019)

The involvement of FATP1 regulating skeletal muscle fat deposition in stressed broilers was affected by fatty acid substrates
por: Wang, Minghui, et al.
Publicado: (2022)

Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation
por: Wu, You, et al.
Publicado: (2021)

Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
por: Li, Shan, et al.
Publicado: (2018)

Quinoa Ameliorates Hepatic Steatosis, Oxidative Stress, Inflammation and Regulates the Gut Microbiota in Nonalcoholic Fatty Liver Disease Rats
por: Zhong, Lingyue, et al.
Publicado: (2023)

Inhibition of phospholipase D1 ameliorates hepatocyte steatosis and non-alcoholic fatty liver disease
por: Wang, Huan, et al.
Publicado: (2023)

The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2020)

Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease
por: Behari, Jaideep, et al.
Publicado: (2021)

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
por: Lee, Hyo Young, et al.
Publicado: (2019)

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
por: Lee, Na Young, et al.
Publicado: (2021)

Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease
por: Li, Yuchang, et al.
Publicado: (2021)

LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway
por: Chen, Xue-Yang, et al.
Publicado: (2019)

Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice
por: Tao, Linfen, et al.
Publicado: (2020)

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
por: Ding, Jiexia, et al.
Publicado: (2015)

Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and β-oxidation
por: Du, Tingwan, et al.
Publicado: (2023)

Myeloid-specific blockade of Notch signaling ameliorates nonalcoholic fatty liver disease in mice
por: Ding, Jian, et al.
Publicado: (2023)

Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice
por: Yuan, Youwen, et al.
Publicado: (2022)

Erratum: The p66shc-Mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2020)

Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease
por: Yang, Hye Ran
Publicado: (2013)

Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats
por: Li, Donghao, et al.
Publicado: (2017)

Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2
por: Qian, Xiaoli, et al.
Publicado: (2021)

Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway
por: Guo, Yi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4he58ffr5k5mmf7e73ke31ufha